Zydus Lifesciences' North American market sales see strong growth, profit surges unexpectedly
Special Topic: Focus on US Stock Market Q4 2025 Financial Reports
On Monday, Indian pharmaceutical company Zydus Lifesciences Ltd released its financial report, showing that third-quarter profits exceeded market expectations, driven by the launch of new drugs in its largest market, North America.
For the quarter ended December 31, the company reported consolidated profits of 10.42 billion Indian rupees (approximately $115.1 million), up from 10.24 billion Indian rupees in the same period last year.
According to data compiled by London Stock Exchange Group, analysts had previously expected the company’s quarterly profit to decline to 9.32 billion Indian rupees.
The company’s overall revenue increased by 30.3% year-on-year, mainly owing to a 16.4% rise in North American sales and a nearly 13% growth in sales in the domestic Indian market.
Core Background
For most Indian generic drug companies, including Zydus Lifesciences, a majority of their revenue comes from the US market. However, these companies are facing pricing pressures due to intense market competition.
Since early 2025, the launch of new drugs—especially those in Zydus’s specialty drug pipeline—has driven the company’s growth in the US market. During this financial reporting period, the company added four new products to the market.
Meanwhile, Zydus’s peers Cipla and Dr. Reddy’s Laboratories both reported sluggish US sales during the same quarter.
Peer Comparison (Next 12-Month Forecast)
Table
| Zydus Lifesciences Ltd | 14.34 | 7.15 | -10.25 | Hold | 29 | 0.88 | 1.24 |
| Alkem Laboratories Ltd | 12.31 | 10.68 | 22.55 | Buy | 11 | 0.81 | 1.38 |
| Dr. Reddy’s Laboratories Ltd | 13.22 | 3.29 | -10.23 | Hold | 39 | 0.93 | 0.64 |
| Cipla Ltd | 15.09 | 7.85 | 0.62 | Hold | 37 | 0.91 | 0.98 |
* Average Analyst Rating: Standardized average based on the rankings “Strong Buy, Buy, Hold, Sell, Strong Sell”
** Price-to-Target Ratio: The ratio of the latest closing price to the average analyst target price. A value above 1 indicates the current stock price is above the target price.
Stock Performance from October to December
Note: All data comes from London Stock Exchange Group
Exchange rate conversion: 1 USD = 90.5590 Indian rupees
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana Flips Robinhood Chain to Lead Tokenized Commodities DEX Volume
Indian Rupee cushioned by RBI’s likely intervention, outlook remain fragile
Dell executive: "Agent AI" is different this time, key components (mainly memory and HDD) shortages may last for more than 5 years
Dell Technologies Chief Operating Officer Jeff Clarke stated that proxy AI, by taking on more tasks, continues to drive up computing and storage demands, making this AI infrastructure cycle distinct from traditional hardware upgrade cycles. By 2030, data center computing power is expected to increase by 200 GW, inference token generation will grow 87-fold, and infrastructure demand is likely to continue expanding.
Morgan Stanley Backs Meta (META.US): Muse Ecosystem Continues to Expand, VR Glasses Expected to Become a New Growth Point in 2027
Morgan Stanley maintains an "Overweight" rating on Meta with a target price of $775, and continues to list it as a top pick.
Crypto prices
More
